BMS Gets EC Approval for Opdivo

| By | BMS, Cancer Drugs, European Commission

Bristol-Myers Squibb Company announced that the European Commission (EC) has approved Opdivo (nivolumab) flat dosing schedule of 240 mg infused over 30 minutes every two weeks (Q2W) or 480 mg infused over 60 minutes every four weeks (Q4W) for the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

“The approval of Opdivo two and four-week flat dosing schedule in the adjuvant melanoma setting is an important milestone for patients across the European Union who now have additional treatment flexibility,”

said Ralu Vlad, Pharm.D, development team lead, product design and delivery, Bristol-Myers Squibb.

“Bristol Myers-Squibb is committed to empowering patients with cancer and their families to regain control of their lives through more flexible treatment options that fit their individual needs.”

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.